The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InInflaRx N.V. (Nasdaq: IFRX) announced the presentation of its Phase 3 clinical trial data for vilobelimab at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The data, focusing on the treatment of pyoderma gangrenosum (PG), was featured in a high-profile late-breaker oral presentation in Denver. Vilobelimab is a first-in-class monoclonal antibody designed to target the complement system to manage inflammatory conditions. This presentation marks a significant milestone for the company as it shares late-stage clinical activity and safety results with the global medical community. The successful showcase of Phase 3 results often serves as a critical step toward regulatory filings and potential commercialization. Investors are closely monitoring these developments as they validate InflaRx's therapeutic pipeline and research capabilities.